Home World News EMA Recommends Granting a Marketing Authorisation for Vimseltinib World News EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 301 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR New on NCI’s Websites for August 2024 August 16, 2024 What if we count all that still remains? June 11, 2021 What Are Drug Shortages and How Can They Impact Care for... June 23, 2023 How targeted screening can help the NHS save lives from lung... November 23, 2022 Load more HOT NEWS GPRC5D Is An Active Immunotherapeutic Target in Multiple Myeloma Withdrawal of the Application to Change the EMA Marketing Authorisation for... Alex Trebek Thanks Fans In “Mind-Boggling” Cancer Update. A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is...
